Please Wait
Applying Filters...
menu
    • menu
    FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies

    Data Compilation
    #PharmaFlow

    Pipeline Prospector 2024 highlights: Rise in new breed of biotechs with maiden approvals; GLP-1 meds show promise beyond obesity

    Stock Recap
    #PipelineProspector

    Menu

    cabozantinib (S)-malate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 19,403Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    28/01/2025 Sichuan Elixir Pharmaceuticals
    China
    		 SICHUAN ELIXIR PHARMACEUTICAL CO LTD 39757 CABOZANTINIB SULFATE 2024-03-22 Active II N/A
    28/01/2025 Dr. Reddy\'s Laboratories
    India
    		 DR REDDYS LABORATORIES LTD 38207 CABOZANTINIB HYDROCHLORIDE 2023-03-31 Active II N/A